Anupam Rasayan reports Rs 17,496 crore order book value

Anupam Rasayan India Limited reports a Rs 17,496 crore order book, with Rs 8,136 crore of disclosed commitments marked for commercialisation in FY27 and Rs 2,186 crore in FY28. Its list spans Life Science, Other Specialty Chemical and Battery Chemical arrangements, with stated tenors ranging from one to 10 years.

What makes up Anupam Rasayan’s Rs 17,496 crore order book?

Anupam Rasayan’s 16 listed arrangements with numerical values comprise Rs 8,707 crore in Other Specialty Chemical, Rs 5,789 crore in Life Science and Rs 3,000 crore in Battery Chemical. These values add to the Rs 17,496 crore total stated in the presentation. The list also contains a six-year Other Specialty Chemical contract with a US speciality metal manufacturer whose value is marked confidential.

Other Specialty Chemical is the largest disclosed segment, exceeding Life Science by Rs 2,918 crore, while the single Battery Chemical line contributes Rs 3,000 crore. The presentation classifies 12 of the 17 arrangements as letters of intent, or LOIs, and five as contracts. Those labels describe the form of each arrangement, but the presentation does not give contract-level delivery schedules or revenue-recognition terms.

When are Anupam Rasayan’s listed agreements due for commercialisation?

Anupam Rasayan marks Rs 8,136 crore of disclosed agreements for commercialisation in FY27, Rs 2,186 crore for FY28 and Rs 7,174 crore as commercialized. This timing classification follows the status column for every line with a disclosed value. The US speciality metal manufacturer contract is also marked for FY27 commercialisation, but its value is confidential.

The FY27 group includes a Rs 3,000 crore, five-year Battery Chemical LOI with Elementium signed in Q4FY25; a Rs 2,850 crore, 10-year Other Specialty Chemical LOI with BASEQUEVOLT, S.A signed in Q1FY27; and a Rs 922 crore, 10-year LOI with a Korean multinational signed in Q4FY25. It also includes a Rs 984 crore Life Science LOI with a Japanese chemical company from Q4FY23 and a Rs 380 crore Other Specialty Chemical LOI with an American multinational from Q1FY24.

The FY28 item is a Rs 2,186 crore, five-year Life Science LOI with a Japanese chemical company signed in Q1FY24. The presentation distinguishes this future item from the five Life Science arrangements signed from Q1FY22 through Q4FY22, which total Rs 2,619 crore and are all marked commercialized. Signing quarter therefore differs from the indicated timing of commercialisation.

Which Anupam Rasayan agreements have the largest disclosed values?

Anupam Rasayan’s three largest disclosed commitments are the Rs 3,000 crore Elementium LOI, the Rs 2,850 crore BASEQUEVOLT, S.A LOI and the Rs 2,186 crore Japanese chemical company Life Science LOI. Together they total Rs 8,036 crore. The first two are marked for FY27 commercialisation, while the Japanese chemical company arrangement is marked for FY28.

Among agreements already commercialized, the largest disclosed item is a Rs 1,697 crore, 10-year Other Specialty Chemical LOI with a US multinational signed in Q4FY25. It is followed by a Rs 1,500 crore, seven-year Other Specialty Chemical LOI with a Japanese multinational signed in Q1FY24. The commercialized list also includes a Rs 1,100 crore Life Science LOI signed in Q1FY22 and a Rs 700 crore Life Science LOI signed in Q4FY22.

The order-book list shows a change in the mix of later agreements. The Rs 3,000 crore Battery Chemical commitment appears in Q4FY25, whereas the five Q1FY22 to Q4FY22 arrangements are all in Life Science and total Rs 2,619 crore. Other Specialty Chemical also contains the Rs 2,850 crore BASEQUEVOLT, S.A LOI signed in Q1FY27, the newest dated numerical commitment in the table.

How does Anupam Rasayan link the order book to its growth strategy?

Anupam Rasayan says its multi-year LOIs and long-term customer contracts provide revenue visibility and support partnerships with global innovators. The stated tenors run from a one-year, Rs 108 crore Other Specialty Chemical contract with a US multinational to 10-year LOIs valued at Rs 1,697 crore, Rs 922 crore and Rs 2,850 crore. The presentation does not disclose annual revenue or annual volumes for individual arrangements.

The presentation also describes an integrated platform across critical raw materials, advanced intermediates, fine chemicals and pharmaceutical formulations. TANFAC is identified with hydrofluoric acid and potassium fluoride production, while Jayhawk is associated with aromatic dianhydrides and custom synthesis. These capabilities sit alongside end markets including polymers, electronic chemicals, active pharmaceutical ingredient intermediates, crop protection and Battery Chemicals.

Bliss GVS is presented as the pharmaceutical-formulation component of the platform, with creams, ointments, gels, tablets, capsules and dry syrups listed as products. Anupam Rasayan says Bliss GVS has a pipeline of more than 62 molecules over the next two years, including more than 48 molecules for regulated markets. It also cites the Vevoor facility as Food and Drug Administration approved in its plan to expand the contract development and manufacturing organisation business.

What does Anupam Rasayan’s commercialisation schedule show?

Anupam Rasayan’s schedule places Rs 10,322 crore of disclosed value in future commercialisation categories for FY27 and FY28, compared with Rs 7,174 crore already marked commercialized. The FY27 amount is led by the Rs 3,000 crore Elementium LOI and the Rs 2,850 crore BASEQUEVOLT, S.A LOI. The status labels are consequently more relevant to the timing indicated in the presentation than the signing quarter alone.

The segment timing also differs. Life Science includes Rs 2,619 crore of commercialized FY22 agreements and the Rs 2,186 crore Japanese chemical company LOI scheduled for FY28. Other Specialty Chemical includes both commercialized items such as the Rs 1,697 crore US multinational LOI and several FY27 items, including Rs 922 crore with a Korean multinational. The confidential-value US speciality metal manufacturer contract means the presentation does not quantify its potential contribution to the displayed numerical total or future revenue.

Conclusion

Anupam Rasayan’s presentation shows a Rs 17,496 crore numerical order-book total led by Rs 8,707 crore in Other Specialty Chemical, followed by Rs 5,789 crore in Life Science and Rs 3,000 crore in Battery Chemical. The comparison between Rs 7,174 crore marked commercialized and Rs 10,322 crore scheduled for FY27 and FY28 shows that a larger disclosed portion is tied to future commercialisation milestones.

The next disclosed milestones are FY27 commercialisation for Rs 8,136 crore of identified commitments, including Elementium and BASEQUEVOLT, S.A, followed by the Rs 2,186 crore Life Science LOI scheduled for FY28. Management also outlines a plan to expand the regulated-market pharmaceutical platform, where Bliss GVS reports a pipeline of more than 62 molecules over the next two years.